Does L8683 require prior authorization?

Yes, L8683 requires prior authorization (high confidence). Code explicitly requires prior authorization.

`L8683`, Radiofrequency transmitter (external) for use with implantable neurostimulator

HCPCS/CPT

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Imaging and laboratory/biomarker data used in studies: brain CT or MRI, amyloid PET (e.g., florbetapir), cerebrospinal fluid (CSF) biomarkers (Aβ1-42, total tau, phospho-tau), and APOE ε4 genotyping when reported in trials.
For some interventional procedures/trials, pre-procedure evaluations included medical/neurological and psychological examinations, depression rating scales (e.g., Montgomery–Asberg Depression Rating Scale), and lumbar puncture with CSF analysis.
Documentation of prior/concurrent standard therapies (e.g., use of cholinesterase inhibitors and/or memantine) is often recorded in trials and may be relevant when considering investigational add-on therapies.
None specified in this policy document. (The CPB lists investigational/experimental treatments and codes not covered; it does not define separate documentation requirements for coverage of the listed items.)
None specified in this document excerpt.
No other explicit documentation requirements, prior-authorization criteria, ICD-10 diagnoses, frequency limits, or billing/coding instructions are provided in this document excerpt.

Implantable vagus nerve stimulators are proven and medically necessary for treating epilepsy in individuals who have medically refractory seizures with failure of two or more trials of antiseizure drugs (or intolerable AED effects), are not candidates for epilepsy surgery (or have failed/refuse after shared decision making), and have no history of left or bilateral cervical vagotomy.
None specified. This Clinical Policy Bulletin addresses experimental treatments for Alzheimer's disease and lists treatments considered experimental and investigational (i.e., not established as effective) for this indication.
No explicit covered indications are stated in this document. The document discusses potential therapeutic use in the following conditions:
Alzheimer's disease (AD)
mild cognitive impairment (MCI)
amnestic MCI

ANTHEM-SURG.00026, Deep Brain, Cortical, and Cerebellar Stimulation

ANTHEM-SURG.00158, Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain

ANTHEM-CG-MED-79, Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems

EVICORE-HPLAN-CIGNA-AFCE721BA4F3, Cigna Comprehensive Code List - Effective 03/07/2026

EVICORE-HPLAN-CIGNA-844835841DE9, Cigna Commercial Interventional Pain Management Code List - Effective 03/07/2026

EVICORE-HPLAN-CIGNA_MEDICARE-47F76AA38AE6, Cigna Medicare Advantage Interventional Pain Management Code List - Effective 01/01/2025

CARELON-interventional-pain-management-2024-06-30-for-ohio-medicaid, Interventional Pain Management

CARELON-interventional-pain-management-2025-07-26-for-anthem-bc-ca-commercial, Interventional Pain Management

CARELON-interventional-pain-management-2026-06-14, Interventional Pain Management

CIGNA-0391, Diaphragmatic/Phrenic Nerve Stimulation

UHC-POL-vagus-nerve-stimulation, Vagus and External Trigeminal Nerve Stimulation

AETNA-CPB-0788, Alzheimer's Disease: Experimental, Investigational, or Unproven Treatments

AETNA-CPB-0011, Peripheral Electrical Nerve Stimulation for Pain

AETNA-CPB-0614, Huntington's Disease

AETNA-CPB-0707, Headaches: Invasive Procedures

AETNA-CPB-0253, Vocal Cord Paralysis / Insufficiency Treatments

AETNA-CPB-0755, Motor Cortex Stimulation

AETNA-CPB-0406, Tinnitus Treatments

AETNA-CPB-0374, Trigeminal Neuralgia: Treatments

HUMANA-NERVE-STIMULATION-FOR-URINARY-INCONTINENCE-MA, Nerve Stimulation for Urinary Incontinence

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

L8683, Radiofrequency transmitter (external) for use with implantable neurostimulator

HCPCS/CPT

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Imaging and laboratory/biomarker data used in studies: brain CT or MRI, amyloid PET (e.g., florbetapir), cerebrospinal fluid (CSF) biomarkers (Aβ1-42, total tau, phospho-tau), and APOE ε4 genotyping when reported in trials.
For some interventional procedures/trials, pre-procedure evaluations included medical/neurological and psychological examinations, depression rating scales (e.g., Montgomery–Asberg Depression Rating Scale), and lumbar puncture with CSF analysis.
Documentation of prior/concurrent standard therapies (e.g., use of cholinesterase inhibitors and/or memantine) is often recorded in trials and may be relevant when considering investigational add-on therapies.
None specified in this policy document. (The CPB lists investigational/experimental treatments and codes not covered; it does not define separate documentation requirements for coverage of the listed items.)
None specified in this document excerpt.
No other explicit documentation requirements, prior-authorization criteria, ICD-10 diagnoses, frequency limits, or billing/coding instructions are provided in this document excerpt.

Implantable vagus nerve stimulators are proven and medically necessary for treating epilepsy in individuals who have medically refractory seizures with failure of two or more trials of antiseizure drugs (or intolerable AED effects), are not candidates for epilepsy surgery (or have failed/refuse after shared decision making), and have no history of left or bilateral cervical vagotomy.
None specified. This Clinical Policy Bulletin addresses experimental treatments for Alzheimer's disease and lists treatments considered experimental and investigational (i.e., not established as effective) for this indication.
No explicit covered indications are stated in this document. The document discusses potential therapeutic use in the following conditions:
Alzheimer's disease (AD)
mild cognitive impairment (MCI)
amnestic MCI